{"filing":{"accession_number":"0001213900-26-090055","cik":"0001788028","ticker":"JSPRW","company_name":"Jasper Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-14","report_date":"2026-08-14","primary_document":"ea0302049-8k_jasper.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1788028/000121390026090055/ea0302049-8k_jasper.htm"},"events":[{"id":27891,"run_id":25468,"accession_number":"0001213900-26-090055","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"The filing discloses Jasper Therapeutics' financial results for the quarter ended June 30, 2026, including condensed consolidated statements of operations and balance sheets, along with a press release reporting Q2 2026 results and corporate updates. This is a standard earnings release disclosure under Item 2.02, furnished as Exhibit 99.1, reporting quarterly financial performance and operational milestones including the completed Kira Pharmaceuticals acquisition and $132 million PIPE financing.","company_name":"Jasper Therapeutics, Inc.","ticker":"JSPRW","filing_date":"2026-08-14","form":"8-K","submitted_at":null,"items":[{"id":29605,"accession_number":"0001213900-26-090055","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The filing discloses Jasper Therapeutics' financial results for the quarter ended June 30, 2026, including condensed consolidated statements of operations and balance sheets, along with a press release reporting Q2 2026 results and corporate updates. This is a standard earnings release disclosure under Item 2.02, furnished as Exhibit 99.1, reporting quarterly financial performance and operational milestones including the completed Kira Pharmaceuticals acquisition and $132 million PIPE financing.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T20:20:26.749632+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":29605,"accession_number":"0001213900-26-090055","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The filing discloses Jasper Therapeutics' financial results for the quarter ended June 30, 2026, including condensed consolidated statements of operations and balance sheets, along with a press release reporting Q2 2026 results and corporate updates. This is a standard earnings release disclosure under Item 2.02, furnished as Exhibit 99.1, reporting quarterly financial performance and operational milestones including the completed Kira Pharmaceuticals acquisition and $132 million PIPE financing.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T20:20:26.749632+00:00","company_name":"Jasper Therapeutics, Inc.","ticker":"JSPRW","filing_date":"2026-08-14"}]}